## NYC ED MAT QUALITY COLLABORATIVE

May 20, 2021

**GREATER NEW YORK HOSPITAL ASSOCIATION** 

Over 100 years of helping hospitals deliver the finest patient care in the most cost-effective way.

# NOTE: Changing Platform from GoToWebinar to Zoom

2

- Moving forward we will be using **Zoom** as a platform to hold the remaining Collaborative sessions
- Instead of registering on a GoToWebinar link, you will receive a calendar invitation with a Zoom link to join
- Let us know of others that should be included or email in the mailing list. You can email me at <u>ccaneda@gnyha.org</u>.

### Welcome to the NYC ED MAT Quality Collaborative

- □ Lines will be muted during the presentation
- Let us know who you are! Please share your name and institution in the chat box! [,\_\_\_]
- To ask a question
  - Type your question in the chat box, if preferred to be anonymous send it directly to Cat
  - Or unmute yourself
- The slides and materials are available in the chat section.
- □ For technical difficulties, please email <u>AVassistance@GNYHA.org</u>



I. Welcome

**II. JHMC Update** 

III. Data Updates and Leveraging Data for Measuring Success

**IV.** Discussion


V. Updates

VI. Next Steps

### <sup>5</sup> ED MAT Collaborative Timeline



## It Takes a Village



## 7 New York MATTERS



#### WHAT IS IT?

New York MATTERS is a collection of resources to initiate care and quickly link patients to appropriate treatment. It utilizes an electronic platform (hosted by the New York State Department of Health) to efficiently refer patients with opioid use disorder to community-based clinics from emergency departments along with OB/GYN offices, correctional facilities, inpatient units, pre-hospital settings, etc.





## 8 New York MATTERS

#### **KEY COMPONENTS**

#### **Medication Voucher Program**

- Vouchers cover up to 14-day buprenorphine/naloxone prescriptions for uninsured patients
- New York MATTERS participates with all Wegmans and Walgreens locations in NYS along with various independently owned pharmacies *Walgreens Wegmans*

#### **Peer Referral**

Patients have the option to be linked with a local peer for support

#### Patient-Centered Approach

- · Patients may choose to seek treatment at any participating New York MATTERS clinic
- Referral process takes place on a tablet, allowing the patient to take ownership of their own referral

For more information about New York Matters visit newyorkmatters.org



#### NY MATTERS' Presentation

- <u>https://www.gnyha.org/event/nyc-ed-mat-quality-collaborative-ny-matters-program/</u>
- Some hospitals are already participating in NY MATTERS and some have expressed interest
- To connect with NY MATTERS program coordinator, email
  Caleigh Loughran at <u>cloughran@buffalomatters.org</u>

## NYC ED MAT QUALITY COLLABORATIVE TEAM UPDATE

#### **GREATER NEW YORK HOSPITAL ASSOCIATION**

Over 100 years of helping hospitals deliver the finest patient care in the most cost-effective way.





#### Jamaica Hospital Medical Center:

#### GNYHA ED MAT Collaborative Project Overview



Melvin Ku MD, MS ED MAT Point Person

## **Our Community**



- Primarily serving South Queens
- Significant African-American, Latino, and West Indian population
- 404-bed tertiary-care hospital with ~117K ED census (pre-COVID)
- Adult Trauma Level 1 Center
- Thrombectomy-capable Stroke Center
- Acute Heart Attack Care (Cardiovascular Interventional Suite)
- Comprehensive Psychiatric Emergency Program (CPEP) including a Psychiatric ED, with Residency Program

## **Current State**



- Capacity to identify patients with OUD/SUD
  - Triage Nurse questions in relation to substance use history
  - Use of COWS score, and clinician screening of those in moderate/severe opioid withdrawal
- Capacity to prescribe and provide buprenorphine in the ED
  - 7 X-waivered ED Attendings, plus 3 whom have finished the 8-hr course
- Capacity to refer patient and connect with community providers
  - 3 outpatient Mental Health Clinics and 2 outpatient Psychotherapy offices

## **Completed ED MAT Strategy**



- We recently implemented our ED MAT Initiative w/in our ED, involving Psychiatry, ED Nursing Leadership, and Pharmacy, and IT
- ED Physicians determine the level of Psychiatry involvement
  - No involvement
  - CASAC
  - Addiction Medicine consultation
- EPIC order enables ambulatory referral whereby Psychiatry clerks coordinate scheduling with outpatient Mental Health Clinics
- Increasing our X-waivered staff through proactive dialogue, and incentive

#### Data Collection Progress and Strategy for Collecting Collaborative Measures



- We'll be working closely with our IT team to query our patient encounters of those diagnosed with opioid use disorder (OUD)
- Psychiatry Department hired a project supervisor whom we'll collaborate with regarding data analysis
- Need to assure reliable contact information gathered
- % of patients whom received timely outpatient Psychiatry appointments?
- % of patients filling their Suboxone prescriptions
- % of patients whom returned to ED for similar issues @ 1/3/6-month intervals



### Barriers in implementing MAT in the ED

Barrier #1: Increasing the # of X-waivered Providers in the ED

• Encouragement from ED Leadership combined with incentive

Barrier #2: Increasing patient compliance with ED and outpatient pathway

• Greater involvement with CASACs to provide psychosocial support in the ED

### Our Team has been wondering



Our institution is targeting those with moderate/severe opioid withdrawal. Have others expanded this to other clinical scenarios? With what success?

Has review of your internal data led to changes within your existing ED MAT program leading to greater success?

### Discussion




## DATA UPDATE AND LEVERAGING DATA TO MEASURE SUCCESS

Jared Bosk, Vice President, Survey and Outcomes Research, GNYHA Courtney Zyla, Senior Analyst, Survey and Outcomes Research, GNYHA


#### **GREATER NEW YORK HOSPITAL ASSOCIATION**

Over 100 years of helping hospitals deliver the finest patient care in the most cost-effective way.

## <sup>20</sup> ED MAT Collaborative Goals



### <sup>21</sup> Goals of ED MAT Collaborative Measurement



#### What are we using to measure progress? 22

#### Baseline assessment Monthly measures

Г	
	-

Complete as early as possible in the collaborative

_		
Г		

Best practices and interventions tied to the goals

GNYHA reports that compare your results to the collaborative's



Also tied specifically to the goals



Complete monthly and upload to **GNYHA** 



Track your progress over time



Share successes and challenges with the collaborative

## <sup>23</sup> Types of Measures

#### Structural

- What interventions/processes are in place?
  - Assessment

#### Process

- How often are these interventions/processes happening?
  - Assessment
- Monthly Measures

#### Outcome


- How often are certain outcomes happening?
  - Monthly measures

## Goal 1: Increase ED Capacity to Prescribe Buprenorphine

# How will we accomplish this?

24

- More providers who <u>can</u> prescribe buprenorphine
- More providers who <u>do</u> prescribe buprenorphine
- Providers available to prescribe buprenorphine as much as possible




Hospitals reporting each measure each month

## Measure 1.1: # of 'x' waivered prescribers available to prescribe in the ED in the past month

25

Rationale	Assessment Measurement
Increasing the number of 'x' waivered	
prescribers should increase the	waivered prescribers
capacity of ED to prescribe	75% of respondents tracked and
buprenorphine to all eligible patients	monitored 'x' waivered prescribers in the
and provide same-day access to	ED and provided information to non-
evidence-based treatment	waivered prescribers to complete training

Average # of 'x' Waivered Prescribers Available to Prescribe in the ED in the Past Month



## <sup>26</sup> Additional Measures for Goal One


Measure	Rationale	Assessment Measurement
Measure 1.2: # of 'x' waivered prescribers who prescribed buprenorphine in the ED in the past month	Helps hospitals determine how many of their 'x' waivered prescribers are actually prescribing buprenorphine	
Measure 1.3: # of days in the past month where an 'x' waivered prescriber was available to prescribe	Increasing the number of days where 'x' waivered prescribers are working in the ED should increase the capacity of the ED to prescribe buprenorphine to all eligible patients	In-person and phone availability for 'x' waivered prescribers
Measure 1.4: # of prescribers working in the ED in the past month	Provides a denominator for Common Measure 1.1	

# Goal 2: Identifying Patients for Buprenorphine Induction in the ED

## How will we accomplish this?


27

- Put in place processes to identify patients with OUD
- Increase ability to identify patients with OUD
- Determine if patients with OUD meet criteria to receive buprenorphine



Hospitals reporting each measure each month

### <sup>28</sup> Goal 2 – How measures relate to each other



# Measure 2.1: # of patients eligible for buprenorphine induction in the ED in the past month

Rationa	e
i tationa	

29

Increasing this measure should directly lead to more patients being induced in the ED and starting treatment for withdrawal. It should also indirectly increase the number of patients who receive a prescription for buprenorphine

#### **Assessment Measurement**


## Strategies for discussing buprenorphine

50% of respondents discuss buprenorphine with patients actively in withdrawal or those who express interest

# Measure 2.2: # of patients identified with Opioid Use Disorder (OUD) in the past month

30

Rationale	Assessment Measurement
Increasing the number of patients who are identified as having OUD should increase the number of patients eligible for buprenorphine induction. It should also indirectly increase the number of patients who receive a	Strategies for identifying patients with OUD 75% of respondents identify patients with OUD via informal conversations and 50% use a formal screening
prescription for buprenorphine.	process



Average # of Patients Identified with Opioid Use Disorder

## Measure 2.3: # of patients screened for Substance Use Disorders (SUD) in the ED in the past month

#### Rationale

31

Increasing screening for SUD should directly lead to an increase in patients identified with OUD, patients determined eligible for buprenorphine induction, and patients induced in the ED

#### **Assessment Measurement**

## How robust are patient screenings for SUD/OUD


- 63% of respondents use a standardized screening tool, 50% of respondents use tools specifically tailored to opioids and 38% use tools more general regarding substance use
- Only 13% screen all patients; 38% screen patients when staff is available and 38% screen when there is suspicion patient has a SUD

# Goal 3: Increasing Provision of Buprenorphine in the ED

# How will we accomplish this?

32


- Increase number of eligible patients who want buprenorphine
- Implement different processes to ensure that interested patients can get buprenorphine



Hospitals reporting each measure each month

## <sup>33</sup> Measure 3.1: # of patients induced on buprenorphine in the ED in the past month


#### Rationale **Assessment Measurement** The primary goal of the Buprenorphine protocols, training, accessibility, and Collaborative is to communication to patients increase the number of 50% of respondents had a protocol in place to provide OUD patients with buprenorphine OUD patients being treated with 75% of respondents with protocol have the protocol available ٠ through the EMR and use COWS and a conversation to buprenorphine determine buprenorphine eligibility 75% of respondents with protocol do not make it known to • patients that ED offers buprenorphine



### <sup>34</sup> Buprenorphine Inductions to Date

#### Total Buprenorphine Inductions To Date: 63

# of Patients Induced on Buprenorphine in the ED



## <sup>35</sup> Additional Measures for Goal Three


Measure	Rationale	Assessment Measurement
Measure 3.2: # of patients given a prescription for a home induction in the ED in the past month	The primary goal of the Collaborative is to increase the number of OUD patients being treated with buprenorphine	Do protocols allow for and encourage this?
Measure 3.3: # of patients given a prescription for buprenorphine upon discharge from the ED in the past month	Patients who have been induced should also receive a prescription to ensure they can continue their treatment, in case there is a delay in getting an appointment with a community provider	Do protocols allow for and encourage this?

# Goal 4: Improving Connections with Community OUD Providers

# How will we accomplish this?

36

- Implement processes to ensure OUD patients can quickly and easily see community OUD providers



Hospitals reporting each measure each month

# Measure 4.1: # of patients linked to OUD treatment at discharge from the ED in the past month

#### Rationale

37

Linking patients to OUD providers increases the chance that they will either maintain the buprenorphine treatment they began in the ED, or begin treatment in the outpatient setting

#### **Assessment Measurement**

- 75% of respondents have a preferred list of community SUD providers
- Two-thirds of respondents evaluate community SUD providers on scheduling availability, hours of operation, availability of needed services, and proximity to the hospital

## <sup>38</sup> How to make the measures work for you

## Assessment

- Review results with team
- Prioritize interventions to implement
- Review periodically to determine progress and priorities

# Monthly Measures

- Review data with team each month
- Create dashboard or reports to share with team and senior leadership
- Identify areas for improvement or to explore further

## To Those Who Have Not: Please Submit Requested Information for Data Contact and Stipend

39

 Please fill-out the requested information below and send to <u>Cat Caneda</u>, <u>ccaneda@gnyha.org</u>, and Jared Bosk, jbosk@gnyha.org, using "NYC ED MAT -Data Collection and Stipend" in the email subject line.

Health System and Facility
Name of Health System:
Name of Hospital Facility:
Data Contact
Name:
Job Title:
Phone #:
Email:
Payable Check Designee
Name:
Address:
Phone #:
If you are required to notify a specific department to receive this stipend, please provide their information:

## Discussion



## **Emergency Medicine Half-Half Medication for Addiction Treatment (MAT) Virtual Waiver Training**



www.pcssNOW.org pcss@aaap.org

41



## <sup>42</sup> Collaborative Activities

## □Office Hours:

Scheduled and invited all 13 sites to participate

- □ 10 already participated
- 2 upcoming Office Hours

## <sup>43</sup> Office Hours: Frequently Asked Questions So Far

- How do you increase acceptance of MAT in the emergency department among clinicians?
- How do you increase clinician comfort with buprenorphine induction and prescription?
- How are patients not in withdrawal or those recently reversed with naloxone from a non-fatal overdose managed?
- Do you collaborate with addiction consult or addiction department when a patient with OUD is identified?
- What is the impact of buprenorphine induction in flow of ED?

## <sup>44</sup> Poll: Are you interested in additional Office Hours?

# Resources to Address Patient Ambivalence to MOUD

### Guidance and Communication Tools for Providers

- PCSS: Motivational Interviewing: Brushing up on the Basics
- PCSS: Motivational Enhancement Techniques: Working with Patients with Substance Use Disorders or High-Risk Use
- NIDA: Motivating Patient Videos

#### Patient Education Handouts

45

PCSS: Common Questions and Concerns about Medication Assisted Treatment (MAT): A Handout for Ambivalent Patients



- FORE: Promoting Equity in Access to Opioid Use Disorder Treatment and Supports: A Focus on Black Communities
- □ AHA: People Matter, Words Matter
- SAMHSA Evidenced Base Guide Series: Use of Medication Assisted Treatment in Emergency Departments

## U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES RELEASES NEW PRACTICE GUIDELINES


- The U.S. Department of Health and Human Services has published new practice guidelines regarding buprenorphine prescribing for opioid use disorder effective April 28, 2021. The new practice guidelines state:
  - Eligible providers can now treat up to 30 patients without completing the previously required training
  - Eligible providers must still submit a <u>Notice of Intent (NOI)</u> to prescribe buprenorphine and will still receive an "X" DEA number
  - Qualified providers include physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives with a valid medical license and valid Drug Enforcement Administration (DEA) registration
  - To treat more than 30 patients, providers must undergo required training. This can be completed online. Click <u>here</u> for more information
- □ For more information, please visit <u>SAMHSA's FAQ page</u>.

47

# <sup>48</sup> Sharing Success Stories



## <sup>49</sup> Knowledge Sharing Session



## 50 Next Steps

### Continue reporting on progress and knowledge sharing session with other hospitals in the Collaborative

## ✓ Get your \$5000 stipend!

- Complete Assessment if you have not already done so
- Submit monthly Collaborative Measures

## <sup>51</sup> Upcoming Collaborative Activities

#### **• Next ED MAT Collaborative webinar:**

- Thursday, June 17, 2021 12 p.m. 1 p.m.
- Topic: NYC DOHMH ED MAT Resources and Process for Buprenorphine Induction and Prescription in the ED
  - Note: Anticipate to receive calendar invitation with a Zoom link

### **o Scheduling Underway**

- Office Hours with an ED Champion
- Data 2000 X Waiver trainings (July)
- Increasing collaboration with community-based providers

• Other member needs???

## <sup>52</sup> Questions or Comments?



## <sup>53</sup> Contact Information



#### **Alison Burke**

Vice President, Regulatory and Professional Affairs, GNYHA aburke@gnyha.org 212-506-5526



Jared Bosk

**GNYHA** 

Vice President, Survey and Outcomes Research,

jbosk@gnyha.org

212-554-7247



Catrina Caneda Project Manager, Behavioral Health Initiatives, GNYHA ccaneda@gnyha.org 212-506-5519



Courtney Zyla Senior Analyst, Survey and Outcomes Research, GNYHA czyla@gnyha.org 212-259-5115